Biotech leaders weigh potential impacts of healthcare reform
Work on landmark law not done
Biotechnology companies must advocate for careful implementation of the federal healthcare reform law in order to protect a climate of innovation in Massachusetts, said speakers at today’s MassBio Policy Leadership Breakfast.
“This industry has been and continues to be vital to the Massachusetts and regional economy, and continues to make an impact that has improved the lives of patients around the world. I am confident this industry is poised for continued growth— but only if we maintain an environment that protects innovation and access to cutting edge therapies,” said Robert K. Coughlin, President & CEO of MassBio.
“We now face the largest challenge, our industry and ultimately patients have ever faced. If this extremely cumbersome and complex law is not implemented close to flawlessly, it could mean the end to innovation, as we know it,” he said.
MassBio Chairman Geoff Cox encouraged biotech companies and other industry stakeholders to engage in the implementation dialogue.
“When the debate is over, we have to know that our voice has been heard,” he said.
The annual Policy Leadership Breakfast serves to bring leaders from the biotechnology and life sciences industry together with policy makers. Speakers at the 2011 event included Glen Shor, Executive Director of the Commonwealth Health Insurance Connector Authority, Christie Hager, Regional Director of the U.S. Department of Health & Human Services, Kenneth I Kaitin, Director of the Tufts Center for the Study of Drug Development and Professor of Medicine and Professor of Pharmacology & Experimental Therapeutics, Edward (Ted) Buckley, Chief Economist at Bloomberg Government, Thomas Barker of Foley Hoag, Rep. Aaron Michlewitz and MassBio Board Chairman Geoff Cox.